Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Upadacitinib in RA (csDMARD-IR) in China and Selected Countries
NCT02955212Phase 3Completed
- Sponsor
- AbbVie Inc.
- Start
- Jan 2018
- Primary completion
- Aug 2019
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 3, randomised, double-blind trial in rheumatoid arthritis (RA) comparing Placebo / Upadacitinib 15 mg with Upadacitinib 15 mg (2 arms). Primary endpoint: American College of Rheumatology 20% Response at 12 weeks. Started Jan 2018; status: completed.
02
Drugs
upadacitinib
03
Conditions
rheumatoid arthritis (RA)
Beyond the preview
Go deeper on NCT02955212.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02955212.